Home Proteases Proteasome 억제제 PR-171 (Carfilzomib)

연구용

PR-171 (Carfilzomib) Proteasome 억제제

제품 번호S2853

Carfilzomib (PR-171)은 ANBL-6 세포에서 IC50 <5 nM을 갖는 비가역적 proteasome 억제제로, β5 소단위의 ChT-L 활성에 대해 시험관 내에서 우선적인 억제 효능을 보였지만, PGPH 및 T-L 활성에는 거의 또는 전혀 영향을 미치지 않았습니다. Carfilzomib은 생존 촉진 autophagy를 활성화하고 세포 apoptosis를 유도합니다.
PR-171 (Carfilzomib) Proteasome 억제제 Chemical Structure

화학 구조

분자량: 719.91

바로가기

품질 관리

배치: 순도: 99.75%
99.75

세포 배양, 처리 및 작업 농도

세포주 분석 유형 농도 배양 시간 제형 활성 설명 PMID
MM.1S Growth Inhibition Assay 0-100 nM 48 h IC50 = 10 nM 25312543
NCI-H929  Growth Inhibition Assay 0-100 nM 48 h IC50 = 14 nM 25312543
SUDHL16  Apoptosis Asssay 2.5–3.5 nM 48 h enhances the cell death co-treatment with ACY1215 25239935
SUDHL14 Apoptosis Asssay 2.5–3.5 nM 48 h enhances the cell death co-treatment with ACY1215 25239935
U2932 Apoptosis Asssay 2.5–3.5 nM 48 h enhances the cell death co-treatment with ACY1215 25239935
P-UMSCC-1 Growth Inhibition Assay IC50=11.2 nM 24915039
R-UMSCC-1 Growth Inhibition Assay IC50=2294 nM 24915039
P-Cal33 Growth Inhibition Assay IC50=17.3 nM 24915039
R-Cal33 Growth Inhibition Assay IC50=1112 nM 24915039
Jurkat Growth Inhibition Assay 1-11nM 48 h inhibits the cell proliferation co-treatment with vorinostat 24801128
Jurkat Apoptosis Asssay 8 nM 24/48 h induces apoptosis, caspase activation, and PARP cleavage co-treatment with vorinostat 24801128
UMSCC-22A Apoptosis Asssay 200 nM 24 h induce the cell apoptosis co-treatment with ONX 0912 22929803
UMSCC-22B Apoptosis Asssay 200 nM 24 h induce the cell apoptosis co-treatment with ONX 0912 22929803
1483 Apoptosis Asssay 200 nM 24 h induce the cell apoptosis co-treatment with ONX 0912 22929803
UMSCC-1 Apoptosis Asssay 200 nM 24 h induce the cell apoptosis co-treatment with ONX 0912 22929803
UMSCC-22A Growth Inhibition Assay IC50=38.7 ± 1.0 nM 22929803
UMSCC-22B Growth Inhibition Assay IC50=30.7 ± 9.3 nM 22929803
1483 Growth Inhibition Assay IC50=50.5 ± 11.9 nM 22929803
UMSCC-1 Growth Inhibition Assay IC50=34.6 ± 2.6 nM 22929803
Cal33 Growth Inhibition Assay IC50=49.3 ± 8.9 nM 22929803
PCI-15A Growth Inhibition Assay IC50=70.4 ± 22.6 nM 22929803
PCI-15B Growth Inhibition Assay IC50=39.5 ± 11.0 nM 22929803
OSC-19 Growth Inhibition Assay IC50=18.3 ± 4.2 nM 22929803
SUDHL16 Apoptosis Asssay 2.0-4.0 nM 48 h induces cell death co-treatment with obatoclax 22411899
SUDHL16 Function Assay 2.5 nM 24 h activates JNK, inactivates AKT, up-regulates Noxa, and induces γH2A.X co-treatment with obatoclax 22411899
Granta Growth Inhibition Assay 0-4 nM 48 h induce cell death co-treatment with HADCIs 21750224
SUDHL16 Growth Inhibition Assay 1-4 nM 36 h induce cell death co-treatment with HADCIs 20233973
MOLT4 Function assay 1 hr Inhibition of chymotrypsin-like activity of 20S proteasome in human MOLT4 cells after 1 hr by CellTiter-Glo luminescent assay, IC50 = 0.0051 μM. 19348473
MESSA Cytotoxicity assay 72 hrs Cytotoxicity against human MESSA cells assessed as cell viability after 72 hrs by CellTiter-Glo luminescent assay, IC50 = 0.018 μM. 19348473
MESSA Cytotoxicity assay 72 hrs Cytotoxicity against multidrug resistance transporter expressing doxorubicin resistant human MESSA cells assessed as cell viability after 72 hrs by CellTiter-Glo luminescent assay, IC50 = 0.413 μM. 19348473
RPMI8226 Cytotoxicity assay 72 hrs Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay, IC50 = 0.01319 μM. 24767818
NCI-H929 Cytotoxicity assay 72 hrs Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay, IC50 = 0.02132 μM. 24767818
CCRF-CEM Antiproliferative assay 72 hrs Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay, IC50 = 0.0061 μM. 26231162
RPMI8266 Antiproliferative assay 72 hrs Antiproliferative activity against human RPMI8266 cells after 72 hrs by oxyluciferin luminescence assay, IC50 = 0.0139 μM. 26231162
HCT116 Antiproliferative assay 72 hrs Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay, IC50 = 0.0193 μM. 26231162
A431 Antiproliferative assay 72 hrs Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay, IC50 = 0.0238 μM. 26231162
TOV21G Antiproliferative assay 72 hrs Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay, IC50 = 0.0238 μM. 26231162
RKO Antiproliferative assay 72 hrs Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay, IC50 = 0.0271 μM. 26231162
MM1S Antiproliferative assay 72 hrs Antiproliferative activity against human MM1S cells measured after 72 hrs by MTS assay, IC50 = 0.0015 μM. 27765408
RPMI8226 Antiproliferative assay 72 hrs Antiproliferative activity against human RPMI8226 cells measured after 72 hrs by MTS assay, IC50 = 0.0132 μM. 27765408
LCL Cytotoxicity assay 48 hrs Cytotoxicity against human LCL cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 0.03 μM. 27994734
RD-ES Cytotoxicity assay 48 hrs Cytotoxicity against human RD-ES cells harboring p53 mutant assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 0.043 μM. 27994734
U266 Cytotoxicity assay 48 hrs Cytotoxicity against human U266 cells harboring mutant p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 0.06 μM. 27994734
WE68 Cytotoxicity assay 48 hrs Cytotoxicity against human WE68 cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 0.08 μM. 27994734
IMR90 Cytotoxicity assay 48 hrs Cytotoxicity against human IMR90 cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 0.13 μM. 27994734
MCF10A Cytotoxicity assay 48 hrs Cytotoxicity against human MCF10A cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 0.32 μM. 27994734
SKOV3 Cytotoxicity assay 48 hrs Cytotoxicity against p53 deficient human SKOV3 cells assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 0.32 μM. 27994734
MDA-MB-468 Cytotoxicity assay 48 hrs Cytotoxicity against human MDA-MB-468 cells harboring mutant p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 0.33 μM. 27994734
HNDF Cytotoxicity assay 48 hrs Cytotoxicity against HNDF cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 0.35 μM. 27994734
KGN Cytotoxicity assay 48 hrs Cytotoxicity against human KGN cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 0.45 μM. 27994734
MCF7 Cytotoxicity assay 48 hrs Cytotoxicity against human MCF7 cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis, LD50 = 4.5 μM. 27994734
MCF7 Function assay 35 nM 4 hrs Inhibition of 26S proteasome in human MCF7 cells assessed as accumulation of high molecular weight polyubiquitin-conjugated proteins at 35 nM after 4 hrs by Western blot analysis 27994734
MDA-MB-468 Function assay 35 nM 4 hrs Inhibition of 26S proteasome in human MDA-MB-468 cells assessed as accumulation of high molecular weight polyubiquitin-conjugated proteins at 35 nM after 4 hrs by Western blot analysis 27994734
MM1S Cytotoxicity assay 72 hrs Cytotoxicity against human MM1S cells measured after 72 hrs by MTS assay, IC50 = 0.0015 μM. 28027531
RPMI8226 Cytotoxicity assay 72 hrs Cytotoxicity against human RPMI8226 cells measured after 72 hrs by MTS assay, IC50 = 0.0132 μM. 28027531
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
fibroblast cells qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells 29435139
fibroblast cells qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells 29435139
Daoy qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells 29435139
ANBL-6 Function assay Inhibition of 20S proteasome activity in human ANBL-6 cells, IC50 = 0.01 μM. 29652143
MCF7 Cytotoxicity assay 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 0.0041 μM. 30165344
MDA-MB-231 Cytotoxicity assay 48 hrs Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 0.0044 μM. 30165344
RPMI8226 Cytotoxicity assay 48 hrs Cytotoxicity against human RPMI8226 cells after 48 hrs by MTT assay, IC50 = 0.0067 μM. 30165344
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성

분자량 719.91 화학식

C40H57N5O7

 보관 (수령일로부터)
CAS 번호 868540-17-4 SDF 다운로드 원액 보관

동의어 N/A Smiles CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4

용해도

In vitro
배치:

DMSO : 100 mg/mL (138.9 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : 50 mg/mL

Water : Insoluble

몰농도 계산기

질량 농도 부피 분자량
희석 계산기 분자량 계산기

In vivo
배치:

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

mg/kg g μL

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘

Targets/IC50/Ki
Proteasome
(ANBL-6 cells)
5 nM
시험관 내(In vitro)

Carfilzomib (PR-171)은 다발성 골수종을 포함한 다양한 세포주 및 환자 유래 신생물 세포에서 증식을 억제하고, 내재적 및 외재적 Apoptosis 신호 전달 경로와 c-Jun-N-말단 키나제(JNK) 활성화를 유도했습니다. 이는 향상된 항-MM 활성을 나타내고, 다른 약물에 대한 저항성을 극복하며, (Dex)와 시너지 효과를 나타냅니다. 이 화합물은 β5 서브유닛의 ChT-L 활성에 대해 시험관 내에서 우선적인 억제 효능을 보이며, 10 nM 용량에서 80% 이상의 억제를 나타냅니다. 저용량 Carfilzomib에 짧게 노출되면 β5 구성 20S Proteasome 및 β5i 면역 Proteasome 서브유닛에 대한 우선적인 결합 특이성을 유도합니다. 이 화합물로 펄스 처리된 ANBL-6 세포에서 카스파제 활성 측정을 통해 8시간 후 카스파제-8, 카스파제-9 및 카스파제-3 활성이 크게 증가하여 8시간 후 대조군 세포에 비해 각각 3.2배, 3.9배 및 6.9배 증가했습니다. Carfilzomib 펄스 처리된 세포에서 미토콘드리아 막 무결성은 41%(Q1 + Q2)로 감소했으며, 이는 운반체 처리된 대조군 세포의 75%와 비교됩니다. 다른 연구에서는 조혈 및 고형 악성 종양에 대한 전임상 효과도 보여주었습니다. 이는 골파괴 세포 형성 및 뼈 재흡수를 직접 억제합니다.

키나아제 분석
카필조밉 서브유닛 프로파일링을 위한 효소결합 면역흡착 분석
ANBL-6 세포(2 × 106개/웰)를 96웰 플레이트에 접종하고 Carfilzomib (PR-171)을 0.001~10 μM 용량으로 1시간 동안 처리합니다. 세포를 용해한 다음(20mM Tris-HCl, 0.5mM EDTA), 정제된 용해물을 중합효소 연쇄 반응(PCR) 플레이트로 옮깁니다. 무처리 ANBL-6 세포 용해물을 사용하여 6 μg 단백질/μL 농도부터 시작하여 표준 곡선을 생성합니다. 활성 부위 프로브 [biotin-(CH2)4-Leu-Leu-Leu-epoxyketone; 20 μM]를 첨가하고 실온에서 1시간 동안 배양합니다. 그런 다음 세포 용해물에 1% 도데실 황산나트륨(SDS)을 첨가하여 100°C로 가열하여 변성시킨 다음, 96웰 멀티스크린 DV 플레이트에 웰당 20 μL의 스트렙타비딘-세파로스 고성능 비드와 혼합하여 1시간 동안 배양합니다. 이 비드들을 효소결합 면역흡착 분석(ELISA) 완충액(PBS, 1% 소 혈청 알부민, 0.1% Tween-20)으로 세척하고 4°C에서 밤새 플레이트 셰이커에서 Proteasome 서브유닛에 대한 항체와 함께 배양합니다. 사용된 항체는 마우스 단클론 항-β1, 항-β2, 항-β1i 및 항-β5i, 염소 다클론 항-β2i 및 토끼 다클론 항-β5 (KLH-CWIRVSSDNVADLHDKYS 펩타이드에 대한 친화성 정제 항혈청)를 포함했습니다. 비드들을 세척하고 2시간 동안 고추냉이 과산화효소 접합 2차 염소 항-토끼, 염소 항-마우스 또는 토끼 항-염소 항체와 함께 배양합니다. 세척 후, 비드들을 슈퍼시그널 ELISA 피코화학발광 기질을 사용하여 현상합니다. 발광 검출을 수행합니다. 원시 발광은 표준 곡선과의 비교를 통해 μg/mL로 변환되고 운반체 대조군에 대한 % 억제로 표현됩니다. 곡선 맞춤은 다음 비시그모이드 용량 반응 방정식을 사용하여 생성됩니다: Y = Bottom + (Top-Bottom)/(1 + 10̂((LogEC50 − X) × HillSlope)), 여기서 X는 농도의 로그이고, Y는 % 억제이며, EC50은 50% 효과를 나타내는 이 화합물의 용량입니다.
생체 내(In vivo)

Carfilzomib (PR-171)은 생체 내 이종이식 모델에서 종양 성장을 중간 정도로 감소시킵니다. 이는 지속적 또는 일시적 치료 모방 후 다발성 골수종 세포 생존력을 효과적으로 감소시킵니다. 이 화합물은 또한 비종양성 마우스에서 해면골 부피를 증가시키고, 뼈 재흡수를 감소시키며, 뼈 형성을 향상시킵니다.

참조
  • [4] https://pubmed.ncbi.nlm.nih.gov/21750224/

적용 분야

방법 바이오마커 이미지 PMID
Western blot pERK / ERK / pSTAT5 / STAT5 / pPI3K / PI3K caspase-9 / caspase-8 c-PARP / PARP / caspase-3 Bcl-2 / Bcl-Xl / Mcl-1 / Bik / Bim / Bax / Bak Atg5 / Atg12 / Beclin-1 / LC3-II Noxa / Bik / Puma / Mcl-1 EGFR / HER2 / ER alpha / p-Akt(Ser473) / Akt / p-ERK / ERK / p53 BDP1 / HER2(Tyr1248) / HER2(Tyr1221/Tyr1222) / PARP1 / caspase-7 / p53 Mut HLA class I
S2853-WB1
24590311
Growth inhibition assay Cell viability
S2853-viability1
27655642

임상시험 정보

(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)

NCT 번호 모집 조건 스폰서/협력자 시작일 단계
NCT05552976 Recruiting
Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
 January 10 2023 Phase 3
NCT05675449 Recruiting
Multiple Myeloma
Pfizer
 December 14 2022 Phase 1
NCT05041933 Unknown status
Hematological Diseases
University Hospital Limoges
 September 15 2021 --

기술 지원

취급 설명서

Tel: +1-832-582-8158 Ext:3

다른 문의사항이 있으시면 메시지를 남겨주세요.

이름을 입력해주세요.
이메일을 입력해주세요. 유효한 이메일 주소를 입력해주세요.
저희에게 무엇이든 작성해주세요.

자주 묻는 질문

질문 1:
How should I prepare a solution of it for an ongoing in vivo study?

답변:
It can be dissolved in 2% DMSO/30% PEG 300/dd H₂O at 10 mg/ml as a suspension, and can be dissolved in 2% DMSO/castor oil at 10 mg/ml as a clear solution.